• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Australian government launches review of health and medical research

Australian government launches review of health and medical research

July 12, 2011
CenterWatch Staff

The Australian government has issued the draft terms of reference for a strategic review of health and medical research, according to PharmaTimes.

The review was first announced May 11 by Minister for Mental Health and Aging Mark Butler. Butler has been consulting with the Association of Australian Medical Research Institutes, the Australian Academy of Science, Universities Australia and the trade association for research-based pharmaceutical companies, Medicines Australia, on developing the terms of reference for the initiative.

The Commonwealth Government has been a consistent supporter of health and medical research through the National Health and Medical Research Council (NHMRC), the draft terms of reference say. The NHMRC allocated Aus$784.9 million across its funding schemes in 2010, while the 2011 federal budget included a 4.3% increase in funding for the Council.

The government has also committed Aus$700 million to building and upgrading health and medical research and training facilities across Australia. In addition, there is significant investment in health and medical research by industry and state governments as well as, to a lesser extent, funding from non-governmental organizations and philanthropists.

The government said the research landscape is changing in the face of a number of trends that have emerged over the last two decades, including a shift in the burden of disease towards chronic and mental health conditions, new knowledge and demand for resources arising from human genome mapping and the revolution in information and communications technologies, the larger infrastructure enabled and required by new and emerging technologies, growing recognition of the importance of translating basic research swiftly into clinical practice, and significant reform in the Australian health sector.

“Whereas Australia has been highly successful in research and development ideas up to the proof-of-concept stage, there are significant opportunities to improve our success in turning these discoveries into commercial ventures, as noted in a number of recent studies,” the preamble to the draft terms of reference states.

The strategic review of health and medical research will focus on optimizing Australia’s capacity to produce world-class health and medical research up to 2020, with reference to issues such as the need for Australia to build and retain internationally competitive capacity across the research spectrum, from discovery to translation; expenditure on, and support for, research in Australia by governments, industry, non-governmental organizations and philanthropists; opportunities to leverage additional investment and support for research through the private sector and philanthropy; the relationship between business and the research sector; strategies to ensure that Australia has the research workforce to meet future challenges and opportunities; opportunities to improve collaboration between the research and clinical sectors; the degree of alignment between Australia’s research and the national burden of disease, health priorities, etc.

The federal government intends to announce the Review Panel and associated Terms of Reference by the end of July. The panel is scheduled to hand in its final report by Aug. 31, 2012.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing